Skip to content

Study · Animal study (in vivo) · 2005

5 results

Oxytocin microinjected into dorsal motor nucleus of the vagus excites gallbladder motility via NMDA receptor-NO-cGMP pathway.

Liu CY, Xie DP, Liu KJ, Zhou YQ, Liu JZ

Brain research1 Jan 2005Cited by 6 (Europe PMC)

PMID15680949 (opens in a new tab)DOI10.1016/j.brainres.2004.10.057 (opens in a new tab)PepBankPUB-15680949
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In animals, oxytocin microinjected into the dorsal motor nucleus of the vagus increased the strength of gallbladder phasic contraction in a dose-dependent way.

    In plain wordsIn animals, oxytocin injected into a brain stem area made the gallbladder contract more strongly, and a higher dose had a bigger effect.

    Peptide
    Oxytocin
    Outcome
    IncreaseGallbladder phasic contraction strength
    Study

    n: not reported in source

    Microinjection into dorsal motor nucleus of the vagus with gallbladder pressure recording
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    10-50 nmol/L, 100 nl · microinjection into dorsal motor nucleus of the vagusAs given in this study.

    Source sentences

    Summary
    Microinjection of OT (10-50 nmol/L, 100 nl) dose dependently increased the strength of gallbladder phasic contraction.
    1 context sentence
    Summary · context
    A frog bladder connected with transducer was inserted into the gallbladder to record the gallbladder pressure.

Studies that did not test the peptide alone4

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

  1. 02AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Mechanism

    In animals, the oxytocin receptor antagonist atosiban abolished the excitatory effect of oxytocin on gallbladder motility, and the V1 receptor antagonist did not.

    In plain wordsIn animals, a drug that blocks the oxytocin receptor stopped the gallbladder response to oxytocin; a drug that blocks a vasopressin receptor did not.

    Peptide
    Oxytocin
    Outcome
    DecreaseOxytocin-induced gallbladder excitation with atosiban
    Study

    n: not reported in source

    Microinjection into dorsal motor nucleus of the vagus with gallbladder pressure recording
    Comparator
    Oxytocin alone
    Outcome group
    Receptor activity and mechanism · Gastrointestinal

    Source sentences

    Summary
    The excitatory effect of OT (10 nmol/L, 100 nl) was completely abolished by atosiban (10 mmol/L, 100 nl), the specific OT receptor antagonist, but was not influenced by [deamino-Pen(1), O-Me-Tyr(2),Arg(8)]-vasopressin (10 mmol/L, 100 nl), the V(1) receptor antagonist.
    1 context sentence
    Summary · context
    A frog bladder connected with transducer was inserted into the gallbladder to record the gallbladder pressure.

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  2. 03AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Mechanism

    In animals, the NMDA receptor antagonist ketamine suppressed the gallbladder motor response to oxytocin.

    In plain wordsIn animals, ketamine, which blocks the NMDA receptor, reduced the gallbladder response to oxytocin.

    Peptide
    Oxytocin
    Outcome
    DecreaseOxytocin-induced gallbladder response with ketamine
    Study

    n: not reported in source

    Microinjection into dorsal motor nucleus of the vagus with gallbladder pressure recording
    Comparator
    Oxytocin alone
    Outcome group
    Receptor activity and mechanism · Gastrointestinal

    Source sentences

    Summary
    Pretreatment of ketamine (10 mmol/L, 100 nl), the NMDA receptor antagonist, suppressed the gallbladder motor response to OT
    1 context sentence
    Summary · context
    A frog bladder connected with transducer was inserted into the gallbladder to record the gallbladder pressure.

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  3. 04AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Mechanism

    In animals, the non-NMDA receptor antagonist CNQX did not affect the gallbladder response to oxytocin.

    In plain wordsIn animals, CNQX, which blocks non-NMDA receptors, did not change the gallbladder response to oxytocin.

    Peptide
    Oxytocin
    Outcome
    No significant changeOxytocin-induced gallbladder response with CNQX
    Study

    n: not reported in source

    Microinjection into dorsal motor nucleus of the vagus with gallbladder pressure recording
    Comparator
    Oxytocin alone
    Outcome group
    Receptor activity and mechanism · Gastrointestinal

    Source sentences

    Summary
    but pretreatment of 6-Cyaon-7-Nitroquinoxaline-2,3-(1H,4H)-Dione (CNQX; 10 mmol/L, 100 nl), the non-NMDA receptor antagonist, did not affect it.
    1 context sentence
    Summary · context
    A frog bladder connected with transducer was inserted into the gallbladder to record the gallbladder pressure.

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  4. 05AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Mechanism

    In animals, the nitric oxide synthase inhibitor L-NAME and the guanylyl cyclase inhibitor methyl blue each inhibited the excitatory effect of oxytocin on gallbladder motility.

    In plain wordsIn animals, drugs that block the nitric oxide pathway reduced the gallbladder response to oxytocin.

    Peptide
    Oxytocin
    Outcome
    DecreaseOxytocin-induced gallbladder excitation with L-NAME or methylene blue
    Study

    n: not reported in source

    Microinjection into dorsal motor nucleus of the vagus with gallbladder pressure recording
    Comparator
    Oxytocin alone
    Outcome group
    Receptor activity and mechanism · Gastrointestinal

    Source sentences

    Summary
    Pretreatment of L-NAME (10 mmol/L, 100 nl), the nitric oxide synthase (NOS) inhibitor, or methyl blue (10 mmol/L, 100 nl), the guanylyl cyclase inhibitor, inhibited the excitatory effect of OT on gallbladder motility.
    1 context sentence
    Summary · context
    A frog bladder connected with transducer was inserted into the gallbladder to record the gallbladder pressure.

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:52 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.